Hdl Handle:
http://hdl.handle.net/10147/316669
Title:
Retrospective costing of warfarin
Authors:
Walsh, C; Murphy, A; Kirby, A; Vaughan, C
Publisher:
Irish Medical Journal
Journal:
Irish Medical Journal
Issue Date:
2014
URI:
http://hdl.handle.net/10147/316669
Abstract:
In Ireland, there are four anticoagulants available for prescribing to patients with atrial fibrillation for stroke prevention. A key feature of the three most recent anticoagulants is that monitoring is redundant. Despite this, there is continued prescribing of the incumbent anticoagulant, warfarin, which requires monitoring. Lack of information regarding the cost of monitoring, and the extra burden it places on health budgets and patients, motivated this costing study. Using micro costing, the costs of warfarin treatment (including monitoring) was disaggregated and isolated from both the patientsâ and health care providerâ s perspectives in a Cork hospital. Costs to the health care provider per patient per clinic visited were 21.57. Patient costs incurred per patient per clinic were 48.50. Thus, the total costs per patient per visit were 70.07. This result reveals that while the pharmaceutical cost of warfarin is low; it is not an inexpensive therapy when monitoring costs are considered.
Item Type:
Article
Language:
en

Full metadata record

DC FieldValue Language
dc.contributor.authorWalsh, Cen_GB
dc.contributor.authorMurphy, Aen_GB
dc.contributor.authorKirby, Aen_GB
dc.contributor.authorVaughan, Cen_GB
dc.date.accessioned2014-05-08T13:58:35Z-
dc.date.available2014-05-08T13:58:35Z-
dc.date.issued2014-
dc.identifier.urihttp://hdl.handle.net/10147/316669-
dc.description.abstractIn Ireland, there are four anticoagulants available for prescribing to patients with atrial fibrillation for stroke prevention. A key feature of the three most recent anticoagulants is that monitoring is redundant. Despite this, there is continued prescribing of the incumbent anticoagulant, warfarin, which requires monitoring. Lack of information regarding the cost of monitoring, and the extra burden it places on health budgets and patients, motivated this costing study. Using micro costing, the costs of warfarin treatment (including monitoring) was disaggregated and isolated from both the patientsâ and health care providerâ s perspectives in a Cork hospital. Costs to the health care provider per patient per clinic visited were 21.57. Patient costs incurred per patient per clinic were 48.50. Thus, the total costs per patient per visit were 70.07. This result reveals that while the pharmaceutical cost of warfarin is low; it is not an inexpensive therapy when monitoring costs are considered.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journalen_GB
dc.titleRetrospective costing of warfarinen_GB
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen_GB
dc.description.fundingNo fundingen
dc.description.provinceMunsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.